Boston Oncology and King Fahd Medical City (KFMC) Partner to Advance Localized Cell & Gene Therapy in Saudi Arabia
2024年8月1日 - 12:20AM
ビジネスワイヤ(英語)
In a landmark initiative poised to transform healthcare in the
Kingdom of Saudi Arabia, Boston Oncology and King Fahd Medical City
(KFMC) have signed a Letter of Intent to collaborate on the
localization of Cell & Gene Therapy.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240731424463/en/
Representatives from Boston Oncology and
King Fahd Medical City (KFMC), along with His Excellency Eng.
Abdulaziz AlRamaih, Deputy Minister of Health for Planning and
Development, at the signing ceremony for the partnership to advance
localized Cell & Gene Therapy in Saudi Arabia. (Photo: Business
Wire)
The signing ceremony, attended by His Excellency Eng. Abdulaziz
AlRamaih, Deputy Minister of Health for Planning and Development,
marks a significant step forward in advancing the Kingdom’s medical
capabilities and achieving the ambitious goals set forth in Vision
2030.
A Milestone in Healthcare Transformation
Dr. Fahad Al-Ghofaili, KFMC CEO, expressed his enthusiasm:
“Localizing Cell & Gene Therapy in KFMC is an important step to
increase local capabilities in advanced treatments and medical
technologies, contributing to the goals of the Healthcare
Transformation Project.” [Translated from Arabic]
Impact for Patients
Boston Oncology, renowned for its customer-centered model,
brings extensive expertise in localizing technology. Laser-focused
on the real-world needs of patients and hospitals, Boston Oncology
is positioned to provide cutting-edge technologies and Cell &
Gene Therapies through this partnership. This collaboration will
establish a local treatment option, relieving bottlenecks in
therapy provision and improving patient outcomes. The resulting
Research & Development and clinical trials will significantly
contribute to innovative advancements in the healthcare sector of
Saudi Arabia.
Dr. Abdullah Baaj, CEO of Boston Oncology, described the
partnership: “KFMC brings world-class clinicians and
infrastructure, making it a destination for patients throughout the
region. Joining forces to localize Cell & Gene Therapy is a
transformative step towards our mission to impact the lives of one
billion patients.”
About Boston Oncology Cell & Gene Therapy
Boston Oncology is an innovative life science company with a
mission to impact the lives of one billion patients by 2030. With
corporate headquarters in Cambridge, Massachusetts, and operations
throughout the world, the company is focused on bringing
patient-centered solutions and advanced treatment modalities to
growing markets. Its new Cell & Gene Therapy entity establishes
a fully localized offering to deliver personalized treatments that
address the unique genetic profiles of patients. By partnering with
leading medical institutions and leveraging leading-edge
technologies, Boston Oncology CGT is expanding the company’s legacy
of transformative advancements in healthcare.
Learn more at https://bostononcology.com/.
About King Fahd Medical City
King Fahad Medical City (KFMC) in Riyadh, Saudi Arabia, stands
as one of the largest and most rapidly expanding medical complexes
in the Middle East, with a capacity of 1,200 beds. Operating within
the second health cluster, KFMC consists of four hospitals and four
specialized medical centers, offering comprehensive healthcare
services. Known for its advanced medical technologies and high
standard of care, KFMC serves over 30,000 inpatients and 500,000
outpatients annually. The institution is committed to excellence in
clinical services, medical education, research, and continuous
improvement in healthcare.
Learn more at https://www.kfmc.med.sa/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240731424463/en/
Boston Oncology Public Relations:
bo_cgt@bostononcology.com